Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.

Plain-language guide to PMID 10720081 (2000): single-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Somatostatin in 10 patients.

Key Facts

PMID: 10720081
Journal: The Journal of clinical endocrinology and metabolism
Year: 2000
Study type: Randomized Controlled Trial
Authors: Terzolo M et al. (10 authors)
DOI: 10.1210/jcem.85.3.6531

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Somatostatin.

However, no data are available on the characteristics of GH secretion in patients with incidentally discovered adrenal adenomas.

They represent an interesting model for studying GH secretion, as a slight degree of cortisol excess may frequently be observed in such patients who do not present with any clear Cushingoid sign.

Who Took Part

The study group was 10 patients.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, single-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Only one side, usually the patients, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.

In the crossover set-up each of the patients took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.

Plasma IGF-I (RIA after acid-ethanol extraction) was measured in a morning sample.

What Was Measured

The subject headings attached to it are Adenoma, Adrenal Gland Neoplasms, Area Under Curve, Arginine, Body Mass Index, Growth Hormone-Releasing Hormone and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Somatostatin in 10 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2000 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Somatostatin compound page, all human trials.

Our Notes on the Compounds

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.

GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.